APA (7th ed.) Citation

Kowalyszyn, R. D., Fein, L. E., Richardet, M. E., Varela, M. S., Ortiz, E., Micheri, C., . . . Lago, N. (2022). Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study. JCO Global Oncology, 8, 1. https://doi.org/10.1200/GO.21.00276

Chicago Style (17th ed.) Citation

Kowalyszyn, Ruben D., et al. "Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study." JCO Global Oncology 8 (2022): 1. https://doi.org/10.1200/GO.21.00276.

MLA (9th ed.) Citation

Kowalyszyn, Ruben D., et al. "Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study." JCO Global Oncology, vol. 8, 2022, p. 1, https://doi.org/10.1200/GO.21.00276.